Compare · ARGX vs REPL
ARGX vs REPL
Side-by-side comparison of argenx SE (ARGX) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 42.5x REPL ($1.49B).
- REPL has been more active in the news (22 items in the past 4 weeks vs 12 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Replimune Group Inc.
- Price
- -
- -
- Market cap
- $63.27B
- $1.49B
- 1M return
- -
- +182.12%
- 1Y return
- -
- +165.70%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 12
- 22
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest ARGX
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
Latest REPL
- Director Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 4% to 1,362,414 units (SEC Form 4)
- Chief Financial Officer Hill Emily Luisa sold $132,176 worth of shares (9,256 units at $14.28), decreasing direct ownership by 4% to 215,852 units (SEC Form 4) to satisfy withholding tax
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-3ASR filed by Replimune Group Inc.
- Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
- Chief Executive Officer Patel Sushil sold $510,253 worth of shares (39,341 units at $12.97), decreasing direct ownership by 5% to 708,151 units (SEC Form 4) to cover taxes
- Chief Financial Officer Hill Emily Luisa sold $148,481 worth of shares (11,448 units at $12.97), decreasing direct ownership by 5% to 225,108 units (SEC Form 4) (for tax liability)
- Chief Medical Officer Xynos Konstantinos sold $148,468 worth of shares (11,447 units at $12.97), decreasing direct ownership by 5% to 224,215 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Schwendenman Andrew sold $98,987 worth of shares (7,632 units at $12.97), decreasing direct ownership by 7% to 99,425 units (SEC Form 4) (withholding tax)